96 related articles for article (PubMed ID: 8019445)
1. Retinal microvascular changes following bone marrow transplantation: the role of cyclosporine.
O'Riordan JM; FitzSimon S; O'Connor M; McCann SR
Bone Marrow Transplant; 1994 Jan; 13(1):101-4. PubMed ID: 8019445
[TBL] [Abstract][Full Text] [Related]
2. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
[TBL] [Abstract][Full Text] [Related]
3. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings.
Kupari M; Volin L; Suokas A; Timonen T; Hekali P; Ruutu T
Bone Marrow Transplant; 1990 Feb; 5(2):91-8. PubMed ID: 2138043
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic bone marrow transplantation for acute myelogenous leukemia, acute lymphocytic leukemia, and multiple myeloma following preparation with busulfan and cyclophosphamide (BuCy2).
Copelan EA; Biggs JC; Szer J; Thompson JM; Crilley P; Brodsky I; Klein JL; Kapoor N; Harman GS; Avalos BR
Semin Oncol; 1993 Aug; 20(4 Suppl 4):33-8; quiz 39. PubMed ID: 8342074
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic family-unrelated bone marrow transplantation in acute and chronic myeloid leukemia.
Fauser AA; Köchling G; Digel W; Finke J; Thiel M; Heinz J; Bross KJ; Dölken G; Mertelsmann R
Bone Marrow Transplant; 1993; 11 Suppl 1():83. PubMed ID: 8448558
[No Abstract] [Full Text] [Related]
6. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in chronic phase following preparation with busulfan and cyclophosphamide.
Galimberti M; Polchi P; Lucarelli G; Angelucci E; Baronciani D; Giardini C; Gaziev D; Erer B; Ripalti M; Rapa S
Bone Marrow Transplant; 1994 Feb; 13(2):197-201. PubMed ID: 8205089
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia.
Stockschläder M; Hegewisch-Becker S; Krüger W; tom Dieck A; Mross K; Hoffknecht M; Berger C; Kohlschütter B; Martin H; Peters S
Bone Marrow Transplant; 1995 Nov; 16(5):663-7. PubMed ID: 8547863
[TBL] [Abstract][Full Text] [Related]
9. [Bone marrow transplantation-associated thrombotic microangiopathy manifested by visual disturbance].
Nakai K; Tajima K; Kishimoto Y; Katsura K; Kawamura M; Yamamoto Y; Hanada M; Zen K; Amakawa R; Fujimoto M; Fukuhara S
Rinsho Ketsueki; 2000 Jan; 41(1):25-31. PubMed ID: 10695395
[TBL] [Abstract][Full Text] [Related]
10. Successful allogeneic bone marrow transplantation in juvenile CML: conditioning or graft-versus-leukaemia effect?
Rassam SM; Katz F; Chessells JM; Morgan G
Bone Marrow Transplant; 1993 Mar; 11(3):247-50. PubMed ID: 8467291
[TBL] [Abstract][Full Text] [Related]
11. Atypical retinal microvasculopathy after bone marrow transplantation.
Bylsma GW; Hall AJ; Szer J; West R
Clin Exp Ophthalmol; 2001 Aug; 29(4):225-9. PubMed ID: 11545420
[TBL] [Abstract][Full Text] [Related]
12. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
13. CNS toxicity and high-dose busulphan in three patients undergoing bone marrow transplantation.
Vasta S; Scimé R; Indovina A; Majolino I
Haematologica; 1992; 77(2):189. PubMed ID: 1398309
[No Abstract] [Full Text] [Related]
14. Allogeneic bone marrow transplantation following busulfan and 90 mg/kg of cyclophosphamide.
Avalos BR; Klein JL; Kapoor N; Copelan EA
Bone Marrow Transplant; 1993 Dec; 12(6):655-8. PubMed ID: 8136749
[TBL] [Abstract][Full Text] [Related]
15. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.
Hirabayashi N; Goto S; Ishii M; Yuge M; Mitsuma A; Noda N
Bone Marrow Transplant; 1998 Jun; 21(11):1079-83. PubMed ID: 9645568
[TBL] [Abstract][Full Text] [Related]
16. [Unrelated donor allogenetic marrow transplantation in treatment of acute and chronic leukemia].
Huang H; Lin M; Meng H
Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):263-7. PubMed ID: 11798883
[TBL] [Abstract][Full Text] [Related]
17. Detection of minimal residual disease and persistence of host-type hematopoiesis: a study in 28 patients after sex-mismatched, non-T cell-depleted allogeneic bone marrow transplantation for Philadelphia-chromosome positive chronic myelogenous leukemia.
Elmaagacli AH; Becks HW; Beelen DW; Stockova J; Bützler R; Opalka B; Schaefer UW
Bone Marrow Transplant; 1995 Dec; 16(6):823-9. PubMed ID: 8750276
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
Matsuyama T; Kojima S; Kato K
Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporine-induced retinal toxic blindness.
López-Jiménez J; Sánchez A; Fernández CS; Gutiérrez C; Herrera P; Odriozola J
Bone Marrow Transplant; 1997 Aug; 20(3):243-5. PubMed ID: 9257893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
